{
    "clinical_study": {
        "@rank": "97627", 
        "arm_group": {
            "arm_group_label": "RIG-C", 
            "arm_group_type": "Experimental", 
            "description": "Single 20 IU/kg dose of RIG-C by intramuscular injection"
        }, 
        "brief_summary": {
            "textblock": "This is a single-arm, open-label study of Rabies Immune Globulin (Human),\n      Caprylate/Chromatography Purified (RIG-C), in approximately 12 healthy subjects.  The\n      purpose of this study is to characterize the rabies virus-specific antibody titer after a\n      single intramuscular injection of 20 IU/kg RIG-C and to evaluate the safety and tolerability\n      of RIG-C."
        }, 
        "brief_title": "An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rabies", 
        "condition_browse": {
            "mesh_term": "Rabies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  In good health in the judgment of the Investigator as determined by medical history,\n             physical examination, and screening laboratory assessments.\n\n          -  Female of childbearing potential must have a negative result on the screening serum\n             pregnancy test and must agree to practice contraception by a method of proven\n             reliability (includes abstinence) for the duration of the study.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females.\n\n          -  Clinical evidence of any significant acute or chronic disease that may interfere with\n             successful completion of the trial.\n\n          -  Clinically significant history of the following: cardiovascular disease,\n             hyperlipidemia, serious respiratory disease including bronchitis or asthma, endocrine\n             disorder, liver disease, glaucoma, gastrointestinal disease, disorder of the\n             reticuloendothelial system, or neurologic illness.\n\n          -  History of angioedema or nephrotic syndrome.\n\n          -  Non-controlled arterial hypertension.\n\n          -  Anemia at screening.\n\n          -  Significant proteinuria (> 1 + on urine dipstick) and/or has a history of acute renal\n             failure and/or severe renal impairment or a blood urea nitrogen or creatinine more\n             than 2.5 times the upper limit of normal at screening and/or currently receiving\n             dialysis.\n\n          -  Elevated liver enzymes (aspartate transaminase, alanine aminotransferase) and\n             Gamma-glutamyl Transferase) equal to or greater than 1.5 times the upper limit at\n             screening.\n\n          -  Previously received the rabies vaccine and/or rabies immune globulin.\n\n          -  Received infusion of a blood/plasma product or fraction within the past 12 months,\n             including any type of immune globulin.\n\n          -  Known adverse reaction to administration of any immune globulin or other blood/plasma\n             products.\n\n          -  Experienced anaphylactic shock with the administration of blood/plasma products.\n\n          -  Known medical history of selective immunoglobulin A (IgA) deficiency.\n\n          -  Received any corticosteroids, immunosuppressants, or immunomodulators within 6 weeks\n             prior to screening.\n\n          -  Expects to receive oral or topical non-steroidal anti-inflammatory drugs (NSAIDs),\n             acetaminophen, antihypertensives, and/or antihistamines 24 hours before or after\n             investigational product administration during the Baseline/Treatment, Study Day 0\n             visit.\n\n          -  Currently receiving any anti-viral treatment.\n\n          -  Screening laboratory results indicative of an acute or chronic infection with\n             hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human\n             immunodeficiency virus (HIV), or parvovirus B19 (B19V).\n\n          -  Participated in another clinical trial within 30 days prior to screening (imaging\n             studies without investigative treatments are permitted) or has received any\n             investigational products within the previous 3 months.\n\n          -  Not willing to postpone receiving any live virus vaccines until 3 months after\n             receiving investigational product.\n\n          -  History of a psychiatric illness requiring hospitalization.\n\n          -  Known substance or prescription drug abuse in the past 12 months.\n\n          -  Any active medical illness that the Investigator may consider a potential confounding\n             condition that would interfere with the study visits and/or procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139657", 
            "org_study_id": "GTI1301"
        }, 
        "intervention": {
            "arm_group_label": "RIG-C", 
            "intervention_name": "RIG-C", 
            "intervention_type": "Biological", 
            "other_name": "Rabies Immune Globulin (Human), Caprylate/Chromatography Purified"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rabies", 
            "Rabies virus", 
            "Rhabdoviridae", 
            "Rabies immune globulin", 
            "Rabies antibodies", 
            "Passive rabies immunization"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tempe", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85283"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single-arm Study to Evaluate the Safety and Antibody Titers Specific to the Rabies Virus in Healthy Subjects After Receiving a Single Dose of Intramuscularly Administered Rabies Immune Globulin (Human)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rabies Virus Antibody Titer", 
            "safety_issue": "No", 
            "time_frame": "10 days post-RIG-C dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of subjects who discontinue due to adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "21 days"
        }, 
        "source": "Grifols Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grifols Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}